Nykode Therapeutics As

Greetings, and welcome to the NICO Therapeutics Q1 2025 Financial Results Presentation. At this time, all participants are in listen-only mode. If anyone would require operator assistance, please press star zero on your telephone keypad. A question and answer session will follow the formal presentation. You may ask a question at any time by typing it into the Ask a Question feature on your screen. As a reminder, this conference is being recorded. It's now my pleasure to introduce our host, Michael Ensig, CEO of Nyco Therapeutics. Please go ahead, Michael.

Thank you very much, Kevin. And also from my side, a very warm welcome to all participants to this webcast for our first quarter results and updates from the business. A quick reminder of our forward-looking statements. Assuming you're all familiar with this kind of forward-looking statements, we will move on. As usual, I am very happy to have with me here today, André Frederiksen, our Chief Scientific Officer and Head of Business Development and Co-Founder, as well as Hal Guren, our Chief Financial Officer. And together we'll try to take you through a deep dive in the business update and the financial numbers for the first quarter. So, happy to report that we have finalized the organizational streamlining that we set out to do and announced in the beginning of the year we have finalized that in the first quarter and will maintain a very strong focus on cost control in the company going forward which will in turn allow us to execute on our future priorities which we look forward to update you on in the near future We have also had Susanne Stauffer selected as Chair of the Board at the Extraordinary General Assembly on the 23rd of April. We have included a very brief bio on the right of this slide here, which we will invite you to read further. We also announced the approved dividend of one NOC Norwegian kroner per share, which was approved at the Annual General Meeting. 26th of May and we have announced that we will provide an update and further details to the company's strategy and priorities in connection with the second quarter results for 2025 which we expect towards the end of August this year here and once again I want to take the opportunity to express our gratefulness and thankfulness for the continued commitment from our employees as well as our shareholders. In addition to those events, we have also seen a good string of data come out from the research labs. So we did publish the final phase two data from our B1016 CO2 trial. in the peer-reviewed BMG GTC journal. The data did, as we have announced earlier, confirm the prolonged benefits and vaccination effect that we also saw in the interim analysis. We'll have one slide on that a little bit later. We did also in the first quarter present a string of new preclinical data from our immune tolerance platform which again demonstrates the APC-targeted platform's ability to modulate multiple arms of the immune system, again, supporting a broad application in autoimmune disorders. And now Nidhi will take us further into the key data from that presentation. We will be presenting new data from the two trials, VB1016-CO2, as well as VB10-Neo-NO2 at the upcoming ASCO, which starts in a few days. Again, highlighting the potential of NICO's immunotherapy platform to induce robust and durable new responses across multiple tumor types. And we'll take you a little bit further into those data. I'll also just a little bit heads up reminding everybody limits to what we can publish before the active posters are released. Switching to VP1016, our lead clinical assets. As mentioned, we were very happy to see the final data released in the B&E journal in the beginning of the year. a peer-reviewed journal with a high impact factor, which again underscores the importance and significance of these data. As we have previously highlighted, the publication also again mentions the favorable safety profile BB1016 in combination with the Tase Release Map in 52 patients. It confirmed the durable efficacy with a medium overall survival of 24.7 months and an objective response rate of 29.2 months in the PL1 positive subgroup. There's a lot of other good, interesting data in that publication, so we're just here drawing your attention to a few of the ones here. And again, most importantly, is a general information of seen consistently with VP1016. We are heading to ASCO now to present further data from the same trial. So the journal did present the final key analysis on the primary and most important points, but we will continue to release data as we dig further into the data pool. So we expect a lot of further interesting insight coming out of this trial in the coming period. And we'll be presenting some of those at the ASCO in a couple of days. And we've just drawn the attention to a few of those. It does see an association between the T cell response, the HPV16 specific T cell response, and patients with reduced systemic immunosuppression during treatment. We also see an association between tumor microenvironment characteristics and response rates. Both of these provide interesting insights into both the mechanism of action of the vaccine as well as the ability to target the appropriate most optimal patient populations in the future.

Again, here we do find